The worldwide weight-loss revolution
<p>GLP-1 weight-loss drugs such as Ozempic, Wegovy, Mounjaro and Zepbound are reshaping the treatment of obesity around the world. But even when these medicines are judged “cost-effective”, access often depends on who can afford to pay. In the second episode of our Business Daily series on the global weight-loss economy, Sam Fenwick examines how different countries are funding — or rationing — access to these high-priced injections. In England, the state's National Health System says the drugs offer good value …
ལས་རིམ་འདི་ད་ལྟ་ར་ཡིག་སྒྱུར་མ་བྱས་ཡོད།
Use STT.ai to transcribe this episode with AI. Get accurate text with speaker detection, timestamps, and export in multiple formats.